Quantum News
Sign InSign Up
Back to News
research

ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
ARS Pharmaceuticals reported its first full-year commercial results in Q4 2025, marking a transition from development to market execution under CEO Richard Lowenthal’s leadership. Revenue growth was driven by its flagship neffy epinephrine nasal spray, with commercial infrastructure expansion and physician education cited as key priorities for 2026. CFO Kathleen Scott highlighted cost management efforts, though specific financial figures weren’t detailed in the transcript excerpt, emphasizing forward-looking guidance risks per SEC disclosures. Analysts from Raymond James, Oppenheimer, and William Blair probed market adoption strategies, signaling investor focus on neffy’s competitive positioning against injectable epinephrine alternatives. The call underscored 2026 goals: scaling production, securing payer coverage, and accelerating prescriber uptake amid an evolving anaphylaxis treatment landscape.
AI Audio Summary
0:00 / 0:00
Click to play
97f3403c-cafd-4120-938d-c54e631f918d.jpeg
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts158.89K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call March 9, 2026 8:30 AM EDT Company Participants Justin Chakma - Chief Business OfficerRichard Lowenthal - Co-Founder, President, CEO & DirectorEric Karas - Chief Commercial OfficerKathleen Scott - Chief Financial Officer Conference Call Participants Anthony DeLise - Raymond James & Associates, Inc., Research DivisionAndreas Argyrides - Oppenheimer & Co. Inc., Research DivisionLachlan Hanbury-Brown - William Blair & Company L.L.C., Research DivisionKevin Holder - ROTH Capital Partners, LLC, Research Division Presentation Operator Good morning, and welcome to ARS Pharmaceuticals Fourth Quarter and Full Year 2025 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I will now turn the call over to Justin Chakma, Chief Business Officer. Please go ahead. Justin ChakmaChief Business Officer Good morning, and thank you for joining our fourth quarter and full year 2025 earnings conference call. With me on the call are Richard Lowenthal, our Co-Founder, President and CEO; Eric Karas, our Chief Commercial Officer; and Kathy Scott, our Chief Financial Officer. Earlier this morning, we issued a press release detailing our financial results and commercial highlights for the fourth quarter and full year 2025. That press release and the slide presentation that we will refer to during today's call are available in the Investors and Media section of our website. Before we begin, please note that today's remarks may contain forward-looking statements. Actual results may differ materially. Please refer to our press release and SEC filings for further risk disclosures. With that, I'll turn the call over to Rich. Richard LowenthalCo-Founder, President, CEO & Director Thank you, Justin. Good morning, everybody, and thank you for joining us. 2025 was our first full year for ARS as a commercial company. It was a year focused on building infrastructure, educating the market and learning as we introduce

Read Original

Tags

drug-discovery

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.